Comparison
Melanotan 2 vs PT-141: Comparing the Research
Same scaffold, different destinies. One stayed a broad, unapproved tanning peptide; the other was refined into an approved medicine for sexual desire.
The gist
If you are comparing melanotan 2 vs pt-141, the simplest way to think about it is parent and child. Melanotan 2 came first: a ring-shaped peptide that switches on all five melanocortin receptors — the cell switches that control skin color, appetite, and sexual function — so it does a bit of everything. PT-141, also called bremelanotide, was built from that same molecule but tuned to mostly hit one receptor, MC4R, the one tied to sex and appetite, while doing far less to skin color.
The practical difference is huge. PT-141 went through full clinical trials and is an approved prescription drug for low sexual desire in some women. Melanotan 2 was never approved for anything and is sold illegally as tanning injections. So they share a chemical ancestor and a brain mechanism, but only one has the trials, the manufacturing controls, and the regulatory sign-off behind it. The rest of this page lays out exactly where they split.
Shared ancestry, deliberate divergence
Both peptides descend from alpha-MSH, the body's natural melanocortin hormone, and both were shaped at the University of Arizona melanocortin program [1]. Melanotan 2 is the cyclic, non-selective parent — it activates MC1R (pigment), MC3R and MC4R (energy and sexual function), and MC5R [1].
PT-141 (bremelanotide) was developed specifically from the Melanotan 2 scaffold as "a melanocortin agonist for the treatment of sexual dysfunction," engineered toward MC4R-mediated sexual effects with reduced pigmentation activity [6]. In other words, the chemists kept the part of Melanotan 2 that drove libido and erections and pared back the part that drove tanning. That single design choice is why the two compounds end up in completely different places.
The evidence base is not symmetrical
Melanotan 2's human evidence is thin and old: a three-person pigmentation pilot [2] and a ten-person erectile-dysfunction crossover study [3], plus a historical/regulatory review [4]. No Phase 2 or Phase 3 trial of Melanotan 2 itself was ever completed [4].
PT-141's evidence went all the way. A randomized, placebo-controlled functional-MRI study in premenopausal women with hypoactive sexual desire disorder found that MC4R agonism with bremelanotide significantly increased self-reported sexual desire and altered activation of brain regions including the insula during erotic stimuli [7]. That mechanistic and clinical work supported its approval for low sexual desire in some women. The asymmetry is the headline: a finished, approved drug versus an abandoned research compound that survived only as a black-market product.
What each one is actually used for now
PT-141 / bremelanotide is a prescription medicine, administered under medical supervision for a specific approved sexual-desire indication. Its effects on skin pigment are minimal by design [6].
Melanotan 2 is used, off any label and against regulator warnings, primarily for tanning — and secondarily for the appetite suppression and libido effects users notice [8]. Because it is non-selective, those extra effects are not bonuses so much as unavoidable consequences of hitting every melanocortin receptor at once, which is also the source of much of its documented harm [12]. A separate cousin, afamelanotide (Melanotan I), occupies a third niche entirely: approved for the rare light-sensitivity disease erythropoietic protoporphyria [5]. Three peptides, three fates, one receptor family — and only the parent, Melanotan 2, has no approval and no quality control behind it.
Where the two genuinely overlap
The comparison is not all contrast. Both peptides act on the same central MC4R circuitry to influence sexual function, which is precisely why one was carved out of the other [6]. The functional-MRI evidence that MC4R agonism increases sexual desire and reshapes brain activation during erotic cues was generated with the Melanotan 2-derived analog, and it speaks to the mechanism the parent compound shares [7]. The 1996 Melanotan 2 pilot's accidental observation of hours-long erections [2], and the 1998 finding of erections in eight of ten men with psychogenic erectile dysfunction [3], are the early human signals that made the whole melanocortin-for-sexual-function program — including PT-141 — worth pursuing in the first place.
So if you are asking melanotan 2 vs pt-141 purely on mechanism, they are close relatives working through overlapping central pathways. The divergence is in selectivity, evidence, and oversight — not in the basic biology of how a melanocortin agonist reaches the circuits that govern desire and erection.
The bottom line on Melanotan 2 vs PT-141
Reduced to essentials: PT-141 is a focused, MC4R-leaning, fully-developed, approved sexual-function medicine with minimal pigment activity [6] [7]. Melanotan 2 is a broad, non-selective, never-approved peptide whose tanning, appetite, and sexual effects all travel together — and whose documented harms (melanoma, renal infarction, priapism) flow from that same lack of selectivity [12] [10]. They share a scaffold and a brain mechanism, but one carries the weight of completed trials and manufacturing controls while the other survives only as an unregulated black-market product [4] [8]. For the broader explainer of the parent compound, see what is melanotan 2.